Table 3.
# | Compound | Human hallucinogenic potency (dose range in mg) | Arithmetic mean of the dose range | Salt form | Routea | Reference | |
---|---|---|---|---|---|---|---|
1 | LSD | 0.06 – 0.2 | 0.13 mg | 326 nmol | Hemitartrate | PO | (Shulgin and Shulgin 1997) |
2 | AL-LAD | 0.08 – 0.16 | 0.12 mg | 343 nmol | Hemitartrate | PO | (Shulgin and Shulgin 1997) |
3 | SS-LSZ | 0.1 – 0.3 | 0.2 mg | 487 nmol | Hemitartrate | PO | Erowid.com “common” |
4 | 25I-NBOMe | 0.5 – 0.7 | 0.6 mg | 1.29 μmol | Hydrochloride | SL or BUC | Psychonautwiki.org “common” |
5 | DOB-DFLY | 0.2 – 0.8 | 0.5 mg | 1.51 μmol | Hydrochloride | PO | (Trachsel et al. 2013) |
6 | 25I-NBOH | 0.5 – 0.9 | 0.7 mg | 1.83 μmol | Hydrochloride | SL or BUC | Psychonautwiki.org “common” |
y | 25D-NBOMe | 0.8 – 1 | 0.9 mg | 2.49 μmol | Hydrochloride | SL or BUC | Psychonautwiki.org “common” |
s | DOB-FLY | 1 | 2.99 μmol | Hydrochloride | PO | (Shulgin et al. 2011) | |
9 | £-(-)-DOI | 1 – 2.3 | 1.65 mg | 5.14 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
10 | DOB | 1 – 3 | 2 mg | 6.44 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
11 | DOC | 1.5 – 3 | 2.25 mg | 8.45 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
12 | DOET | 2 – 6 | 4 mg | 15.4 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
13 | 5-MeO-AMT | 2.5 – 4.5 | 3.5 mg | 17.1 μmol | Freebase | PO | (Shulgin and Shulgin 1997) |
14 | DOM | 3 – 10 | 6.5 mg | 26.5 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
15 | DOBU | 10 | 34.7 μmol | Hydrochloride | PO | (Braun et al. 1978) | |
16 | 2C-B-FLY | 10 – 18 | 14 mg | 43.7 μmol | Hydrochloride | PO | Psychonautwiki.org “common” |
17 | 2C-I | 14 – 22 | 18 mg | 52.4 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
18 | Psilocybin | 10 – 20 | 15 mg | 52.8 μmol | Freebase | PO | (Shulgin and Shulgin 1997) |
19 | 4-HO-DIPT | 15 – 20 | 17.5 mg | 59.0 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1997) |
20 | 5-MeO-DALT | 12 – 25 | 18.5 mg | 60.3 μmol | Hydrochloride | PO | Erowid.com “common” |
21 | 2C-B | 12 – 24 | 18 mg | 60.7 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
22 | 4-HO-MPT | 20 – 30 | 25 mg | 71.8 μmol | Fumarate | PO | Psychonautwiki.org“common” |
23 | 4-HO-DET | 10 – 25 | 17.5 mg | 75.3 μmol | Freebase | PO | (Shulgin and Shulgin 1997) |
24 | 4-HO-MIPT | 12 – 25 | 18.5 mg | 79.6 μmol | Freebase | PO | (Shulgin and Shulgin 1997) |
25 | 3C-P | 20 – 40 | 30 mg | 104 μmol | Hydrochloride | PO | Tripsit.me “common” |
26 | TMA-2 | 20 – 40 | 30 mg | 115 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
27 | MEM | 20 – 50 | 35 mg | 146 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
28 | Proscaline | 30 – 60 | 45 mg | 163 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
29 | 3C-E | 30 – 60 | 45 mg | 163 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
30 | DPT | 30 – 70 | 50 mg | 178 μmol | Freebase | IM | (Faillace et al. 1967; Soskin et al. 1973) |
31 | Escaline | 40 – 60 | 50 mg | 191 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
32 | DET | 50 – 70 | 60 mg | 277 μmol | Freebase | IM | (Boszormenyi et al. 1959; Szara et al. 1966) |
33 | DMT | 50 – 100 | 75 mg | 398 μmol | Freebase | IM | (Szara 1957; Gillin et al. 1976) |
34 | MDA | 80 – 160 | 120 mg | 556 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
35 | TMA | 100 – 250 | 175 mg | 669 μmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
36 | Mescaline | 178 – 356 | 267 mg | 1.08 mmol | Hydrochloride | PO | (Shulgin and Shulgin 1991) |
BUC, buccal; IM, intramuscular; PO, orally; SL, sublingually.